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Original article
Newly developed and validated eosinophilic esophagitis histology scoring
system and evidence that it outperforms peak eosinophil count
for disease diagnosis and monitoring
M. H. Collins,1 L. J. Martin,2 E. S. Alexander,3,6 J. Todd Boyd,1 R. Sheridan,1 H. He,2 S. Pentiuk,4
P. E. Putnam,4 J. P. Abonia,5 V. A. Mukkada,4 J. P. Franciosi,4 M. E. Rothenberg5
Divisions of 1Pathology and Laboratory Medicine, 2Human Genetics, 3Biostatistics and Epidemiology,
4Gastroenterology, 5Allergy and Immunology, University of Cincinnati, and 6Department of Health Services
Administration, Xavier University, Cincinnati, Ohio, USA
SUMMARY. Eosinophilic esophagitis (EoE) is diagnosed by symptoms, and at least 15 intraepithelial eosino-
phils per high power field in an esophageal biopsy. Other pathologic features have not been emphasized. We devel-
oped a histology scoring system for esophageal biopsies that evaluates eight features: eosinophil density, basal
zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces (DIS), surface epi-
thelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of
abnormalities were scored using a 4-point scale (0 normal; 3 maximum change). Reliability was demonstrated by
strong to moderate agreement among three pathologists who scored biopsies independently (P £ 0.008). Several
features were often abnormal in 201 biopsies (101 distal, 100 proximal) from 104 subjects (34 untreated, 167
treated). Median grade and stage scores were significantly higher in untreated compared with treated subjects
(P £ 0.0062). Grade scores for features independent of eosinophil counts were significantly higher in biopsies
from untreated compared with treated subjects (basal zone hyperplasia P £ 0.024 and DIS P £ 0.005), and were
strongly correlated (R-square >0.67). Principal components analysis identified three principal components that
explained 78.2% of the variation in the features. In logistic regression models, two principal components more
closely associated with treatment status than log distal peak eosinophil count (PEC) (R-square 17, area under the
curve (AUC) 77.8 vs. R-square 9, AUC 69.8). In summary, the EoE histology scoring system provides a method to
objectively assess histologic changes in the esophagus beyond eosinophil number. Importantly, it discriminates
treated from untreated patients, uses features commonly found in such biopsies, and is utilizable by pathologists
after minimal training. These data provide rationales and a method to evaluate esophageal biopsies for features in
addition to PEC.
KEY WORDS: eosinophilic esophagitis, pathology, pediatrics, scale.
INTRODUCTION
Eosinophilic esophagitis (EoE), a relapsing chronic dis-
ease, is diagnosed by clinical symptoms, lack of response
to proton pump inhibitor therapy, and eosinophil-rich
inflammation in esophageal biopsies.1–3 Peak eosinophil
count (PEC), 15 intraepithelial eosinophils in at least
one high power field (HPF), in an esophageal biopsy is
the gold standard for the pathologic portion of the diag-
nosis. Reduced PEC constitutes an endpoint in clinical
trials of therapies for EoE, and is a common goal in
clinical management.1–8 However, rereview of slides with
PECs 1–14/HPF yields counts at or above the diagnostic
threshold value in >20% of such biopsies, a limitation
of using PEC as the sole pathologic diagnostic feature.9
Pathology other than eosinophil-rich inflammation
has been described in EoE: basal zone hyperplasia
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(BZH), dilated intercellular spaces (DIS), and thick-
ened lamina propria fibers (LPF) are commonly seen.
Only quantifying eosinophils has been emphasized in
the diagnosis and treatment of EoE, yet standard
methods to evaluate and quantify other common path-
ologic features could increase reproducible results
(multiple pathologists using uniformmethods to count
eosinophils in esophageal biopsies achieve nearly per-
fect interobserver agreement10) and diagnostic yield (a
comprehensive esophageal biopsy scoring system that
includes inflammation and other pathologic variables
distinguishes patients who have gastroesophageal
reflux disease from control subjects11).
The current focus of EoE pathology evaluation is the
maximum severity of eosinophil inflammation (EI), i.e.
PEC. Severity is an important metric, but the amount
of diseased tissue may also be important. Indeed, for
other inflammatory diseases affecting the bowel both
severity (grade) and extent (stage) of inflammation pro-
vide important clinical information.12–14
Our objective is to develop and validate a histologic
scoring system (HSS) to objectively evaluate grade and
stage of multiple pathologic features in esophageal
biopsies from patients with EoE.We show that pathol-
ogists can successfully use the HSS after minimal train-
ing. Importantly, the EoEHSS both provides
information not imparted by PEC, and better discrimi-
nates esophageal biopsies by EoE therapy status com-
paredwith PEC.
MATERIALS ANDMETHODS
Three EoE cohorts were evaluated: #1 patients
(N5 41; 79 biopsies, 41 proximal, 38 distal) prospec-
tively recruited for a study correlating PEC with symp-
toms,15 some of whom participated in a prospective
placebo-controlled study of swallowed fluticasone pro-
pionate to treat EoE4; #2 well-characterized EoE
patients (N5 40; 79 biopsies, 40 proximal, 39 distal)
prospectively recruited to develop a patient reported
outcome scale16; #3 randomly selected patients
(N5 23; 43 biopsies, 20 proximal, 23 distal) under-
going endoscopy as part of ongoing clinical care (July
16-August 21, 2012; see Supporting Information for
additional information). Study subjects and/or their
legal guardians from cohorts #1 and #2 signed
informed consent forms. Cohort #3 was designed to
capture a random set of patients; therefore, not all had
consented for research. A Health Insurance Portability
and Accountability Act (HIPAA) waiver of consent
was obtained from the Institutional Review Board
(IRB) to assess data of individuals who did not sign
consent forms. This study was performed with the
approval of the Cincinnati Childrens Hospital Medi-
cal Center (CCHMC) IRB.
Eight features of esophageal biopsies were defined
and evaluated. EI was graded using PEC obtained by
counting eosinophils in the most densely inflamed
HPF (Fig. 1, Supporting Information Fig. S1). Addi-
tional features were BZH: >15% of the total epithelial
thickness (Fig. 1A); eosinophil abscess (EA): solid
mass of intraepithelial eosinophils (Fig. 1B); eosino-
phil surface layering (SL): linear alignment of eosino-
phils parallel to the epithelial surface (Fig. 1B); DIS:
spaces around squamous epithelial cells that exhibit
intercellular bridges (Fig. 1A, Supporting Information
Fig. S1); surface epithelial alteration (SEA): surface
epithelial cells that exhibit altered tinctorial properties,
manifest as dark red staining, with or without intraepi-
thelial eosinophils (Supporting Information Fig. S1A);
dyskeratotic epithelial cells (DEC): individual cells
with deeply eosinophilic cytoplasm and hyperchro-
matic nuclei (Supporting Information Fig. S1B); LPF:
thickened connective tissue fibers in the lamina propria
(Fig. 1A). Each feature was scored separately for grade
(severity) or stage (extent) of abnormality using a 4-
point scale (05 normal; 35most severe or extensive).
Expanded definitions and detailed scoring methods
are provided in Supporting Information.
Fig. 1 EoE biopsies. (A) EI is present (arrows). BZH (bar) occu-
pies >66% of total epithelial height (grade 3). Intercellular bridges
in DIS (arrowheads) are easily identified at 100X (grade 3). LPF
fibers exceed the diameter of basal cell nuclei (asterisks) (grade 3).
(B) EA (white asterisk) contains more than 20 eosinophils (grade
3). SL (arrows) consists of 5–10 eosinophils in a row (grade 2).
DIS are present (arrowheads).
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MHC used extensive experience to design the HSS,
and scored all biopsies. To determine if others could
similarly use the HSS, MHC invited additional
CCHMC pathologists (JTB, RS) to apply it to biop-
sies encountered in their daily practice. MHC ver-
bally described the features to JTB and RS, who
stated they comprehended the definitions and the
scoring methods, and that the features were present
in EoE biopsies and were worthwhile to evaluate,
thus providing face and content validity of the HSS.
Visual aids, glass slides, or preselected images were
not reviewed as part of training. JTB subsequently
identified esophageal biopsies during his diagnostic
biopsy evaluations that showed a spectrum of
changes from few or no eosinophils to intense eosin-
ophilic inflammation (cohort #3). These biopsies
were independently scored by all three pathologists
who were blinded to patient treatment status, or ther-
apy, at the time that the biopsies were obtained. All
features were evaluated and scored in the section on
the slides showing the most marked pathology.
Data were analyzed using JMPGenomics6.1 (SAS
Institute, Cary, NC, USA). The cohorts were com-
pared using ANOVAs and contingency tables. Interob-
server agreement was evaluated using Kendalls
coefficient of concordance in the R package irr. To
determine agreement across distal and proximal fea-
tures, iotawas estimated for grade and stage.
To compare untreated and treated patients, Wilcoxon
nonparametric test was used for scores and contingency
tables or Fishers exact test for abnormalities. Features
different at the Bonferroni correction threshold
(P 0.05/85 0.00625) are considered statistically signifi-
cant. Features different at the nominal P-value threshold
(P 0.05) should be interpretedwith caution.
Spearman nonparametric correlations between fea-
tures within grade distal, grade proximal, stage distal,
stage proximal were calculated. For each grouping, the
multiple testing significance threshold is 0.0018 (0.05/
28).
To determine if EoEHSS provides information
beyond PEC, non-nested logistic regression models
were compared using R-square and the area under the
curve (AUC). Distal PEC counts were used because
distal esophageal biopsies are virtually always
obtained. Given the high degree of correlation among
features, principal components analysis (PCA) with
varimax rotation was used to develop a composite
score. Due to a substantial degree of missing data for
LPF (lamina propria was not present in many biop-
sies), this variable was excluded from the PCA. DEC
and stage scores for SEA were also removed because
they did not contribute substantially to the first three
principal components (PC). The final PCAwas based
on the distal and proximal EoEHSS grade and stage
scores for EI, BZH, DIS, EA, SL, and grade of SEA
from 194 biopsies (97 subjects with both proximal and
distal biopsies). Using the factor loadings, three com-
posite measures were created: PC1, PC2, and PC3.
Logistic regression models with PC1, PC1—PC2, and
PC1—PC3 were compared with the model with distal
PEC.
RESULTS
Demographics
There were 104 study subjects (90 males, 14 females,
mean age 8.66 years) (Supporting Information Table
S1). Most subjects (82%) were on EoE therapy (diet
therapy, swallowed fluticasone propionate, both, or
systemic prednisone therapy).
Applying EoEHSS: reliability and ease of use
There was strong-to-moderate agreement among path-
ologists (Supporting Information Table S2,P 0.008).
Using PEC as the gold standard (Kendalls coefficient
0.93–0.96), we found equivalent-to-slight reductions
for all features (0.80–0.94) except SEA and SL which
exhibited modest agreement (0.61–0.72 and 0.73–0.88,
Fig. 2 EoEHSS feature frequency. Frequency of histologic abnormalities in untreated (black bars) and treated (gray bars) in distal (A)
and proximal (EoE) biopsies (B). *P 0.05, **P 0.0063 (Bonferroni multiple testing threshold).
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respectively). The multivariate measure of agreement
exhibited moderate-to-strong agreement. Scoring was
accomplished in less than 1 minute by all pathologists.
Frequencies of abnormalities
A total of 201 biopsies were reviewed: 101 (18 un-
treated, 83 treated) from proximal, 100 (16 untreated,
84 treated) from distal esophagus. Frequencies of
abnormalities (grade score 1) for each feature were
similar between distal and proximal biopsies (Fig. 2).
Features commonly abnormal were EI, BZH, DIS,
and LPF. These data support the importance of sys-
tematic survey of pathologic features other than eosin-
ophil counts in inflamed and uninflamed esophageal
biopsies from patients with EoE.
PEC differs by treatment status
PEC was greater in both proximal and distal biopsies
from untreated compared with treated subjects
(P5 0.008) (Table 1). Maximum PEC (greater of prox-
imal and distal counts) was also greater (P5 0.007) in
untreated (median 124; interquartile range (IQR) 69–
172) compared with treated (median 33; IQR 3.5–
126.4) subjects.
EoEHSS grade and stage scores differ
by treatment status
We found marked differences in the grade and stage
scores by treatment status (Tables 1 and 2) for proxi-
mal and distal biopsies (P 0.0062) demonstrating
EoEHSS responsiveness. After multiple-testing correc-
tion (P 0.00625), several grade scores remained asso-
ciated with treatment status: DIS (P5 0.0051) and EI
(P5 0.0035) in distal biopsies; DIS (P5 0.0002), EI
(P5 0.0002), and BZH (P5 0.0001) in proximal biop-
sies. Several stage scores remained significant after
multiple-testing correction: EI (P5 0.0049) and DIS
(P5 0.0002) in distal; EI (P< 0.0001), BZH (P<
0.0001), and DIS (P5 0.0009) in proximal biopsies.
Importantly, grade scores of biopsies from 5/14 (36%)
individuals with 0 eosinophils/HPF exhibited LPF
and/or DIS documenting that alterations may be pres-
ent even if eosinophils are absent.
Correlations among EoEHSS features
The relationships among the different features (Fig. 3)
were similar in proximal and distal biopsies. Based on
clinical experience, EA and SL were anticipated to
relate, and strong correlations for both grade and stage
were found (r2> 0.8). For both grade and stage, EI
correlated strongly with BZH (r2 0.76), and with
DIS (r2 0.68); BZH and DIS were also strongly cor-
related (r2 0.67) consistent with clinical experience.
However, correlations between EI and EA or SL grade
and stage were more attenuated (r2 0.56) than antici-
pated. DEC had low correlations, possibly due to the
lowoccurrence of this feature (Fig. 2).
EoEHSS composite score better explains treatment
status than distal PEC
To determine if the EoEHSS is a better predictor of
treatment status than PEC, we performed PCA to gen-
erate a composite score of the EoEHSS features. The
first three PC explained a cumulative 78.2% of the vari-
ation (57.3, 11.1, and 9.9% for the first, second and
third PC) of EoEHSS features. We then performed
four logistic regression models with treatment status as
the outcome variable and log distal PEC: PC1, PC1-
PC2, and PC1-PC3. The model with log PEC had the
lowest r2 and AUC compared with the models using
PCs (Table 3). PC1 and PC2were associatedwith treat-
ment status (P5 0.0009 and 0.02, respectively). PC1
was a size axiswith similar factor loadings (weightings)
suggesting that elevations across all features were asso-
ciated with being untreated. PC2 was a contrast axis
with DIS positively associated with being untreated
and SL and EA negatively associated with being
untreated.
Table 1 EoEHSS grade scoresa and PEC
Distal Proximal
Untreated Treated P Untreated Treated P
EI 3 (2–3) 2 (1–3) 0.0035 3 (2–3) 1 (0–2) 0.0002
BZH 2 (1–3) 1 (0–2) 0.024 2 (1–3) 0 (0–1) <0.0001
DIS 3 (3–3) 2 (0–3) 0.0051 3 (3–3) 2 (0–3) 0.0002
LPF 2 (2–3) 2 (0–2.5) 0.20 2 (0.75–2.25) 1 (0–2) 0.26
EA 0 (0–1) 0 (0–0) 0.14 0 (0–1) 0 (0–0) 0.041
SL 0 (0–2) 0 (0–0) 0.012 0 (0–1) 0 (0–0) 0.34
SEA 0 (0–0.75) 0 (0–0.75) 0.90 0 (0–0.25) 0 (0–0) 0.45
DEC 0 (0–0) 0 (0–0) 0.19 0 (0–0) 0 (0–0) 0.93
Non-PEC feature mean 0.47 (0.28–0.57) 0.29 (0.08–0.47) 0.0062 0.44 (0.28–0.51) 0.14 (0.05–0.38) 0.0003
PEC 131.5 (24.3–175) 26 (3–93) 0.008 69 (30.3–113.8) 3 (0–44) 0.008
aMedian (IQR). Groups were compared using Wilcoxon rank sum analyses.
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DISCUSSION
We developed an EoEHSS that evaluates both PEC
and additional pathologic features in EoE biopsies.
Pathologists can apply the EoEHSS after minimal
training and without substantially increasing time
required to complete reporting. Many of the assessed
features occur commonly and associate with treatment
status. The EoEHSS composite score better discrimi-
nates treated from untreated patients than PEC, the
current diagnostic gold standard, and also detects
pathology in biopsies devoid of eosinophils, which
may explain post-therapy disease activity. These results
provide rationales and a method to evaluate esopha-
geal biopsies for pathology in addition to PEC.
EoEHSS measures esophageal pathology
reliably and efficiently
Strong to moderate agreement among pathologists
who independently scored biopsies demonstrates
EoEHSS reliability. Successful application after mini-
mal training demonstrates EoEHSS efficiency. Several
factors may facilitate this ease of implementation.
Grading and staging are skills surgical pathologists use
evaluating tumors. Pathologists frequently examine
multiple levels of small biopsies, a habit that aids scor-
ing. Most EoEHSS features are common in EoE biop-
sies and familiar to surgical pathologists. The EoEHSS
evaluates PEC up to, but not over, 60 eosinophils/
HPF. Reducing the time to generate peak counts may
both diminish fatigue from prolonged counting and
Table 2 EoEHSS stage scoresa
Distal Proximal
Untreated Treated P Untreated Treated P
EI 2.5 (1–3) 1 (0–2) 0.0049 2 (1–3) 0 (0–2) <0.0001
BZH 2.5 (2–3) 1 (0–3) 0.0070 3 (1–3) 0 (0–2) <0.0001
DIS 3 (3–3) 1.5 (0–3) 0.0002 2.5 (2–3) 1 (0–3) 0.0009
LPF 3 (2.5–3) 3 (0–3) 0.12 3 (0.75–3) 2.5 (0–3) 0.48
EA 0 (0–1) 0 (0–0) 0.18 0 (0–1) 0 (0–0) 0.042
SL 0 (0–1) 0 (0–0) 0.011 0 (0–1) 0 (0–0) 0.28
SEA 0 (0–0.75) 0 (0–0.75) 0.98 0 (0–0.25) 0 (0–0) 0.40
DEC 0 (0–0) 0 (0–0) 0.19 0 (0–0) 0 (0–0) 0.94
Non-PEC feature mean 0.5 (0.31–0.54) 0.21 (0.04–0.43) 0.0024 0.46 (0.24–0.52) 0.13 (0–0.38) 0.0003
aMedian (IQR). Groups were compared using Wilcoxon rank sum analyses.
Fig. 3 Correlations between features. Panels A–D exhibit heatmaps of the Spearman correlations; A distal grade, B proximal grade, C
distal stage, D proximal stage. Darker colors indicate higher correlation coefficients.
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increase consistency: correlations are generally better
between initial and second reviews for PEC <60/
HPF.9 Thus the EoEHSS is a reliable, efficient method
to evaluate multiple abnormalities in EoE biopsies.
Most EoEHSS abnormalities associate
with treatment status
EI, BZH, DIS, EA, and SL exhibited significant reduc-
tions in treated comparedwith untreated biopsies from
proximal and/or distal biopsies. EoE is defined patho-
logically by eosinophil-rich inflammation in esopha-
geal biopsies and, therefore, pathology scoring systems
must evaluate eosinophils. We, however, identified
reductions in features that do not evaluate eosinophils,
specifically BZH and DIS. The finding of noneosino-
philic features associating with treatment status sup-
ports evaluating biopsies for more than eosinophils.
Scoring systems
A unique aspect of the EoEHSS is separate grade and
stage scores for each feature. Determining the relative
contributions of overall grade and stage scores, as well
as the scores for individual features, to clinical signs
and symptoms could lead to therapy endpoints. The
correlations between the EoEHSS and symptoms is
important to explore because of the lack of correlation
of PEC with some symptom domains in a validated
pediatric EoE symptom questionnaire.16 Indeed, the
effect of specific therapies on the area occupied by
abnormal tissue (stage) has not been well-studied and
is an important metric to pursue in future larger stud-
ies. For example, DIS are correlated with esophageal
impedance abnormalities in EoE17; the relative contri-
butions of DIS grade and stage to abnormal imped-
ance studies could be tested using the EoEHSS. The
effect of concomitant BZH and EI, which correlate
well with DIS, could also be explored.
A previously published scoring system evaluates
both severity and extent of eosinophil granule protein
deposition but requires immunohistochemistry and is,
therefore, not suited to daily pathology sign-out.18 The
EoEHSS does not require use of special stains for fea-
ture recognition or scoring. Unlike the EoEHSS,
another scoring system includes dichotomous scores,
is used for biopsies from untreated subjects only, and
yields final scores averaged among esophageal sites.19
EoEHSS identifies treatment status better than the
gold standard—PEC
An important step in scale development is to compare
a candidate scale to the existing gold standard. An
important characteristic of a diagnostic test is to iden-
tify patients with the target disease, and also to dis-
criminate them from patients who have undergone
therapy, in other words, to identify treatment status.
The subjects in this study were treated using a variety
of therapies and were categorized as being treated
without regard to the type of therapy, only that EoE
therapy had been administered. PEC is the gold stand-
ard for the pathology portion of the diagnosis of EoE;
therefore, we compared the performance of the
EoEHSS composite score and PEC. The EoEHSS
composite score, which includes both grade and stage,
was more strongly associated with treatment status
than log distal PEC as evidenced by greater R-square
and AUC. Importantly, both BZH and DIS were part
of this model, providing additional evidence that fea-
tures not defined by eosinophils are important.
An interesting aspect of one PCAmodel was a nega-
tive association of SL and EA with untreated status.
Perhaps SL and EA indicate disease chronicity; longer
duration of illness among patients already on therapy
than those not yet treated is likely. Future studies relat-
ing these features to duration of illness may be
revealing.
Not all EoEHSS features were included in the mod-
els. LPF was excluded because of a large amount of
missing data. However, LPF will remain in the
EoEHSS until a sufficient number of biopsies in which
lamina propria can be evaluated have been assessed to
makemeaningful conclusions about LPFs utility. Sim-
ilarly, DEC appears disconnected from most EoEHSS
features; however, DEC may yet prove to be an impor-
tant marker of a particular phenotype which can be
identified only with additional HSS-generated data
and experience. At this point, removing any of the
EoEHSS features would be premature until further
scenarios can be examined.
This study was based on clinical practice and did not
include subjects receiving specific therapy according to
a clinical trial protocol. The EoEHSS outperformed
PEC even in this heterogeneous real-world study and
its performance might improve in a rigorous clinical
trial. Prospective studies, including therapeutic trials,
comparing the relative performances of the EoEHSS
and PEC as diagnostic tools should be performed.
Table 3 Logistic modelinga
Parameter P R-square (%) AUC
Log distal PEC PEC 0.006 9.0 69.8
PC1 PC1 0.003 10.6 77.6
PC1-PC2 PC1 0.0009 17.0 77.8
PC2 0.02
PC1-PC3 PC1 0.0006 17.8 78.3
PC2 0.016
PC3 0.42
aA composite measure of the EoEHSS scores was generated using
PCA. Model fit was compared using R-square and AUC. PC1
included EI, BZH, DIS, EA, and SEA proximal and distal grade
and stage scores weighted similarly. PC2 included negative weights
for DIS and positive weights for SL and EA. PC3 included nega-
tive weights for SEA and SL and positive weights for EI.
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Future studies
These data document that evaluating the degree and
extent of multiple pathologic features in EoE biop-
sies improves the ability to identify treated from
untreated biopsies compared with the current gold
standard—PEC. Further, prospective evaluation of
the EoEHSS with respect to patient symptomology
and the EoEHSSs impact on clinical care is required
prior to finalizing this scale. Biopsies from adults
who have EoE do not appear to differ from those
from affected children, but evaluating biopsies from
adults is also required.
In summary, we developed an EoEHSS that quanti-
fies the frequency, severity, and extent of multiple fea-
tures, including features that do not evaluate
eosinophils. Pathologists can apply the HSS reliably
and efficiently with minimal training. Further, the
EoEHSS is more strongly associated with treatment
status than the current gold standard, PEC only.
Therefore, these results provide rationales and a
method to evaluate esophageal biopsies for EoE.
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SUPPORTING INFORMATION
Additional Supporting Information may be
found in the online version of this article at the
publishers web-site and includes:
Figure S1 EoEHSS features in esophageal biopsies
from patients with EoE. (A) SEA manifest as
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increased red staining of the surface layer of epi-
thelium (arrowheads) is associated with few eosin-
ophils large arrows (SEA grade 2). Narrow arrows
point to intercellular bridges in dilated intercellu-
lar spaces. (B) DEC (arrowhead) cytoplasm is
pink, but not as red as eosinophils (arrows), and is
homogeneous, unlike the granular eosinophils.
Supplementary Table S1 Subject demographics
Supplementary Table S2 EoEHSS interobserver
agreement among three pathologists
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